NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



LUM001- Emerging Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 974750
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 10個工作天內
LUM001-新洞察與市場預測:2030年 LUM001- Emerging Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 60 Pages

LUM001是根尖鈉依賴性膽汁酸轉運蛋白(ASBT)的抑製劑,其可將腸內膽汁酸循環回循環系統。通過每天一次口服片劑減少血清膽汁酸,LUM001可以提供減輕與許多膽汁淤積性肝病相關的嚴重瘙癢和進行性肝損傷的新穎治療方法。LUM001已獲得美國食品和藥物管理局(FDA)孤兒產品開發辦公室的孤兒藥稱號,用於治療四種罕見的膽汁淤積性肝病,包括原發性膽汁性肝硬化;進行性家族性肝內膽汁淤積;Alagille綜合徵 和原發性硬化性膽管炎。






本報告全面涵蓋7個主要市場上Alagille症候群臨床實驗藥。提供有關2020-2030年調查期間美國,歐洲5個國家(德國,法國,意大利,西班牙,英國)和日本7個主要市場的LUM001詳細概要。產品詳細內容中包含作用機制,劑量管理,合成途徑,法規的里程碑的研究開發活動,以及其他開發活動。再加上市場預測、 SWOT分析,市場上競爭趨勢,及其他新治療方法等未來市場趨勢。


第1章 藥物概要

  • 產品詳細內容
  • 作用機制
  • 劑量與管理
  • 研究開發活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 市場競爭趨勢

第6章 其他的新治療方法

第7章 附錄

第8章 報告購買選擇

Product Code: DIDM0131

"LUM001- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Alagille syndrome in 7 Major Markets. A detailed picture of the LUM001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.


LUM001 is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), which recycles intestinal bile acids back into the circulation. By reducing serum bile acids with a once-daily oral tablet, LUM001 may offer a novel therapeutic approach for alleviating the severe itching and progressive liver damage associated with many cholestatic liver diseases. LUM001 has received Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) Office of Orphan Product Development in four rare cholestatic liver diseases including primary biliary cirrhosis; progressive familial intrahepatic cholestasis; Alagille syndrome; and primary sclerosing cholangitis.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around LUM001.
  • The report contains forecasted sales for LUM001 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Alagille syndrome.
  • The report also features the SWOT analysis with analyst insights and key findings of LUM001.


The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LUM001 Analytical Perspective by DelveInsight

  • In-depth LUM001 Market Assessment

This report provides a detailed market assessment of LUM001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • LUM001 Clinical Assessment

The report provides the clinical trials information of LUM001 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Alagille syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence LUM001 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Alagille syndrome are giving market competition to LUM001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of LUM001.
  • Our in-depth analysis of the forecasted sales data of LUM001 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LUM001.

Key Questions:

  • Which company is developing LUM001 along with the phase of the clinical study?
  • What is the technology utilized in the development of LUM001?
  • What is the product type, route of administration and mechanism of action of LUM001?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LUM001 development?
  • What are the key designations that have been granted to LUM001?
  • What is the forecasted market scenario of LUM001?
  • What is the history of LUM001 and what is its future?
  • What is the forecasted sales of LUM001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to LUM001?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1: LUM001, Description
  • Table 2: LUM001, Clinical Trial Description
  • Table 3: LUM001, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4: Market Competitors
  • Table 5: Other Emerging Therapies

List of Figures

  • Figure 1: The Development Timeline of LUM001
  • Figure 2: Patent Details, LUM001
  • Figure 3: LUM001, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4: LUM001, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5: LUM001, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6: LUM001, Japan Market Size from 2020 to 2030 (in Millions USD)